Ketoconazole-d4

• CAT Number: S000149
• CAS Number: 1398065-75-2
• Molecular Formula: C26H24D4Cl2N4O4
• Molecular Weight: 535.46
• Purity: ≥95%
• Target: Metabolic Enzyme/Protease
• IUPAC Name: 1-[3,3,5,5-tetradeuterio-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
• InChI: InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3/t23-,26-/m0/s1/i12D2,13D2
• InChIKey: XMAYWYJOQHXEEK-DNYYUWHPSA-N
• SMILES: [2H]C1(CN(CC(N1C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl)([2H])[2H])C(=O)C)[2H]

Ketoconazole-d4 (CAS: 1398065-75-2), a premium pharmaceutical research compound designed for advanced antifungal and antimicrobial studies. As a deuterated analog of Ketoconazole, it offers enhanced stability and improved pharmacokinetic properties. Ketoconazole-d4 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel antifungal therapies. Trusted by leading laboratories, Ketoconazole-d4 is your go-to solution for cutting-edge antifungal research. Unlock new possibilities in infection treatment with Ketoconazole-d4, where innovation meets reliability.

Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]

[2]. Seif El-Din SH, et al. Effect of ketoconazole, a cytochrome P450 inhibitor, on the efficacy of quinine and halofantrine against Schistosoma mansoni in mice. Korean J Parasitol. 2013 Apr;51(2):165-75.
[Content Brief]

[3]. Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res. 1992 Aug;24(8):367-70.
[Content Brief]

[4]. Muindi JR et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 2010 Sep;151(9):4301-12.
[Content Brief]

[5]. Amrita Datta, et al. High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer. Sci Rep. 2018 May 25;8(1):8161.
[Content Brief]